T2619

CH5132799 has been used in trials studying the treatment of Solid Tumors.

SKLB-163 is a small-molecule inhibitor and a RhoGDI inhibitor with oral bioactivity, cell permeability, and selectivity. This compound induces tumor cell apoptosis, inhibits proliferation and migration, and enhances radiosensitivity by downregulating RhoGDI, activating the JNK-1/caspase-3 pathway, and suppressing Akt and p44/42 MAPK phosphorylation.

SKF-107457 is an HIV protease type 1 inhibitor. It is a hexapeptide substrate analog with the scissile bond being replaced by a hydroxy ethylene isostere.

SKLB70326 is a cell-cycle progression inhibitor that acts by inducing G0/G1 phase arrest and apoptosis in human hepatic carcinoma cells.

SN34037 is a specific Aldo-keto reductase 1C3 (AKR1C3) inhibitor capable of reducing PR-104A to PR-104H and inhibiting the cytotoxic activity of PR-104A, suitable for studying PR-104A-responsive leukaemia.